Peptac (Ranitidine HCl) is a histamine H2-receptor antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion.
Peptac is readily absorbed from the GIT with peak plasma concentrations occurring about 2 hours after oral administration. The elimination half-life of ranitidine is approximately 2 hrs.
Peptac is indicated for:
A. Treatment of:
- Duodenal ulcer.
- Benign gastric ulcer.
- Post-operative ulcer.
- Reflux esophagitis.
- Zollinger-Ellison syndrome.
B. Prophylaxis of:
- Recurrent hemorrhage in patients with bleeding peptic ulcers.
- Patients at risk from stress related ulceration of the upper GIT.
- Patients at risk of developing the acid aspiration syndrome during general anesthesia particularly obstetric patients during labour.
Peptac-150 Film Coated Tablets: Each F/C tablet contains Ranitidine Hydrochloride USP equivalent to 150 mg Ranitidine. Blister packs of 20 tablets.
Peptac-300 Film Coated Tablets: Each F/C tablet contains Ranitidine Hydrochloride USP equivalent to 300 mg Ranitidine. Blister packs of 10 tablet